Status:
COMPLETED
REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective, multinational, non-interventional, observational study. A series of cohort studies will be conducted to assess the prevalence of undiagnosed stage 3 CKD in each region. The st...
Detailed Description
This study is a retrospective, multinational, non-interventional observational study. The study does not attempt to test any specific a priori hypothesis; it is descriptive only and will collect data ...
Eligibility Criteria
Inclusion
- At least two consecutive eGFR laboratory tests with values ≥30 and \<60 mL/min/1.73 m2 (Stage 3A or 3B) that are \>90 and ≤730 days apart. The index date is the date of the second eGFR measure meeting the criteria for stage 3 CKD
- At least 12 months of continuous presence in the database or registration in the data prior to the first qualifying eGFR (for data sources with information on enrolment)
- Age ≥18 years at index date
Exclusion
- Solid organ transplant before the study index date
- Any evidence of advanced CKD (stage 4, 5) based on CKD diagnostic codes, or renal replacement therapy before the index date
Key Trial Info
Start Date :
December 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 13 2023
Estimated Enrollment :
1006361 Patients enrolled
Trial Details
Trial ID
NCT04847531
Start Date
December 15 2020
End Date
November 13 2023
Last Update
December 16 2024
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Louisville, Kentucky, United States, 40202
2
Research Site
Cambridge, Massachusetts, United States, 02140
3
Research Site
Ann Arbor, Michigan, United States, 48108
4
Research Site
Sydney, New South Wales, Australia, 2040